Planegg/Martinsried, November 11, 2024.Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused ...

end of press release --- About Medigene AG Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell receptor (TCR)-guided therapies to effectively eliminate cancer ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

These indicators could include, but are not limited to: MDG1: average annual dietary intake per capita; access to employment, including the informal sector and agricultural self-employment ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Moreover, greater gender equality (see Box 2) can also help in the battle to reduce poverty (MDG1) and promote growth—directly by boosting women's participation in the labor force and increasing both ...

Planegg/Martinsried, October 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR) ...

Medigene AG ( (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment ...

Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of ...

Planegg/Martinsried, October 24, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR) ...